$2.14 Million in Sales Expected for Blueprint Medicines Corp (BPMC) This Quarter

Equities analysts predict that Blueprint Medicines Corp (NASDAQ:BPMC) will report sales of $2.14 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Blueprint Medicines’ earnings, with the lowest sales estimate coming in at $1.13 million and the highest estimate coming in at $3.44 million. Blueprint Medicines posted sales of $1.63 million in the same quarter last year, which suggests a positive year over year growth rate of 31.3%. The firm is expected to report its next earnings results on Wednesday, February 20th.

According to Zacks, analysts expect that Blueprint Medicines will report full-year sales of $45.64 million for the current fiscal year, with estimates ranging from $44.61 million to $46.93 million. For the next year, analysts forecast that the business will post sales of $9.03 million, with estimates ranging from $3.62 million to $20.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Blueprint Medicines.

BPMC has been the subject of a number of recent analyst reports. Wedbush reaffirmed an “outperform” rating and set a $103.00 price target on shares of Blueprint Medicines in a report on Monday, January 7th. BidaskClub raised Blueprint Medicines from a “hold” rating to a “buy” rating in a report on Tuesday, January 15th. Zacks Investment Research downgraded Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Tuesday, January 15th. ValuEngine downgraded Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 2nd. Finally, Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Thursday, November 15th. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $103.25.

A number of hedge funds and other institutional investors have recently made changes to their positions in BPMC. BlueMountain Capital Management LLC purchased a new stake in shares of Blueprint Medicines in the 3rd quarter valued at about $140,000. Fernwood Investment Management LLC purchased a new stake in shares of Blueprint Medicines in the 3rd quarter valued at about $210,000. Jane Street Group LLC purchased a new stake in shares of Blueprint Medicines in the 2nd quarter valued at about $206,000. Pacer Advisors Inc. purchased a new stake in shares of Blueprint Medicines in the 3rd quarter valued at about $286,000. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Blueprint Medicines by 16.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,255 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 594 shares during the last quarter.

Shares of NASDAQ BPMC opened at $72.53 on Tuesday. The stock has a market cap of $3.21 billion, a price-to-earnings ratio of -18.52 and a beta of 1.61. The company has a quick ratio of 10.05, a current ratio of 10.05 and a debt-to-equity ratio of 0.03. Blueprint Medicines has a 1 year low of $44.58 and a 1 year high of $109.00.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Featured Story: Why is cost of goods sold important?

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply